menu
    • menu
    [{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Immedica Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Infusion","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Immedica Pharma \/ Immedica Pharma"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Immedica Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Immedica Pharma \/ Immedica Pharma"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Immedica Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immedica Pharma \/ Immedica Pharma"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Immedica Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immedica Pharma \/ Immedica Pharma"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"KKR","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Acquisition","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Approved FDF","graph3":"Immedica Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immedica Pharma \/ KKR","highestDevelopmentStatusID":"15","companyTruncated":"Immedica Pharma \/ KKR"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Immedica Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immedica Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immedica Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Immedica Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Immedica Pharma \/ Immedica Pharma"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Immedica Pharma","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Immedica Pharma \/ Immedica Pharma"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immedica Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immedica Pharma \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immedica Pharma \/ Immedica Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Immedica Pharma

    Menu

    Immedica Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ganaxolone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Ovid Therapeutics

                            Deal Size : $7.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ovid Therapeutics Enters Agreement with Immedica Pharma

                            Details : The agreement aims for strengthening Immedica’s focus on ganaxolone, for the adjunctive treatment of epileptic seizures, by acquiring control of additional intellectual property rights.

                            Product Name : Ztalmy

                            Product Type : Miscellaneous

                            Upfront Cash : $7.0 million

                            June 25, 2025

                            Lead Product(s) : Ganaxolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Ovid Therapeutics

                            Deal Size : $7.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ganaxolone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Marinus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

                            Details : Through the acquisition, Immedica strengthens it's global rare disease business by adding Ztalmy (ganaxalone). It is indicated for the treatment of seizures associated with CDKL5 deficiency disorder.

                            Product Name : Ztalmy

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 30, 2024

                            Lead Product(s) : Ganaxolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Marinus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

                            Details : Pegzilarginase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arginase 1 Deficiency.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 03, 2024

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : KKR

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kkr and Impilo Announce Strategic Partnership in Rare Disease Platform Immedica Pharma

                            Details : KKR and Impilo will support Immedica’s growth, including launching the approved ultra-orphan drug Loargys (pegzilarginase) and continuing in-licensing and M&A activities.

                            Product Name : Loargys

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : KKR

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Aeglea BioTherapeutics

                            Deal Size : $115.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

                            Details : Under the agreement, Immedica gains global rights of AEB1102 (pegzilarginase), a novel recombinant human enzyme engineered to degrade the amino acid arginine, for the treatment of rare metabolic disease Arginase 1 Deficiency.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : $15.0 million

                            July 27, 2023

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Aeglea BioTherapeutics

                            Deal Size : $115.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Immedica Enter Exclusive Partnership for Commercialisation of Cancer Supportive Care Products in C...

                            Details : Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogeni...

                            Product Name : Akynzeo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Apamistamab,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Actinium pharmaceuticals

                            Deal Size : $452.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab...

                            Details : Actinium retains all rights related to Iomab-B in the United States and the rest of the world, and will be responsible for certain clinical and regulatory activities and the manufacturing of Iomab-B.

                            Product Name : Iomab-B

                            Product Type : Radiolabeled Compound

                            Upfront Cash : $35.0 million

                            April 12, 2022

                            Lead Product(s) : 131-I Apamistamab,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Actinium pharmaceuticals

                            Deal Size : $452.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Aeglea BioTherapeutics

                            Deal Size : $151.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase

                            Details : Aeglea BioTherapeutics will supply pegzilarginase, a novel, recombinant human arginase 1 enzyme that has been shown to lower toxic levels of the amino acid arginine in patients with Arginase 1 Deficiency (ARG1-D).

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : $21.5 million

                            March 22, 2021

                            Lead Product(s) : Pegzilarginase

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Aeglea BioTherapeutics

                            Deal Size : $151.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed

                            Immedica Pharma

                            Sweden arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : PharmaMar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PharmaMar Inks Pact with Immedica Pharma to market lurbinectedin in Eastern Europe and Other Territories

                            Details : Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.

                            Product Name : Zepzelca

                            Product Type : Miscellaneous

                            Upfront Cash : $2.1 million

                            April 29, 2020

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : PharmaMar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth